A new AGA clinical practice update (CPU) focuses on sclerosing mesenteritis, a rare and poorly understood disorder of bowel mesentery characterized by inflammation, fat necrosis, and fibrosis. The update offers guidance on diagnosing and treating the condition and a roadmap for future research.
Key takeaway:
In the CPU, experts emphasize the need to better understand the underlying inflammatory mechanisms, including the role of cytokines and other mediators, to develop more targeted therapies with fewer side effects and quicker clinical responses.
Watch as Drs. Mark Worthington and Seth Crockett discuss the prevalence and diagnostic criteria for sclerosing mesenteritis.
Read more in the full AGA CPU published in the May issue of Clinical Gastroenterology and Hepatology.
